Why the study?
How should pediatric cancer patients and survivors be monitored for the development of cardiac toxicities?
How should pediatric cancer patients and survivors be monitored for the development of cardiac toxicities?
This review highlights the importance of long-term cardiac monitoring for childhood cancer survivors as they transition to adult care, given the delayed onset of therapy-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Supports cardiac monitoring in childhood cancer survivors transitioning to adult care; leaves open optimal protocols pending prospective validation.
Joy M. Fulbright (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: